Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results

Journal of Infectious Diseases

Volumn 208, Issue 1, 2013, Pages 32-39

  Gallant, Joel E ^a   Koenig, Ellen ^d   Andrade Villanueva, Jaime ^e   Chetchotisakd, Ploenchan ^f   Dejesus, Edwin ^b   Antunes, Francisco ^g   Arastéh, Keikawus ^h   Moyle, Graeme ⁱ   Rizzardini, Giuliano ^j   Fehr, Jan ^k   Liu, Yapei ^c   Zhong, Lijie ^c   Callebaut, Christian ^c   Szwarcberg, Javier ^c   Rhee, Martin S ^c   Cheng, Andrew K ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c GILEAD SCIENCES   (United States)

^d Instituto Dominicano de Estudio IDEV   (Dominican Republic)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

^f KHON KAEN UNIVERSITY   (Thailand)

^g HOSPITAL DE SANTA MARIA   (Portugal)

^h Vivantes Auguste Viktoria Klinikum   (Germany)

ⁱ CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

cobicistat; HIV; pharmacoenhancer

Indexed keywords

ATAZANAVIR; CHOLESTEROL; COBICISTAT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; RITONAVIR; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; EYE JAUNDICE; FEMALE; FRACTURE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; JAUNDICE; KIDNEY DISEASE; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPINAL CORD COMPRESSION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

COBICISTAT; HIV; PHARMACOENHANCER;

ADENINE; ADULT; ANTI-HIV AGENTS; CARBAMATES; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RITONAVIR; THIAZOLES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84878525908     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit122     Document Type: Article

References (28)

1. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-91.
2. Xu LH, Liu HT, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett 2010; 1:209-13.
3. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS 2011; 25:1881-6.
4. US Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www. aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 2012.
5. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
6. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
7. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: arandomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
8. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
9. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. October 2002. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070968. pdf. Accessed April 2012.
10. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week AIDS 2008; 22:1389-97.
11. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-55.
12. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25:F7-12.
13. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32-40.
14. Lepist E-I, Murray B, Tong L, Roy A, Bannister R, Ray A. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [abstract A1-1724]. In: Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2011.
15. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-78.
16. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-75.
17. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
18. Elion R, Cohen C,Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008; 9:213-24.
19. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-56.
20. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-88.
21. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-60.
22. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50:367-74.
23. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011; 16:339-48.
24. McGrath D, Zhu L, Thiry A, et al. Renal function in treatment-naive subjects exposed to tenofovir/emtricitabine in combination with atazanavir/ritonavir or lopinavir/ritonavir: 48-week results from the CASTLE study (BMS AI424138)[THPE0190]. In: Presented at: 17th International AIDS Conference. Mexico City, 2008.
25. da Silva B, Cohen D, Gibbs S, Fredrick L, Bernstein B. Renal function in treatment-naive subjects exposed to tenofovir/emtricitabine in combination with atazanavir/ritonavir or lopinavir/ritonavir: 48-week results from the CASTLE study (BMS AI424138). In: Program and abstracts of the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (London, UK). London, UK: International Medical Press, 2008.
26. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008; 5:5.
27. Gilead Sciences. Viread (tenofovir disoproxil fumarate) US prescribing information. http://www.gilead.com/pdf/viread-pi.pdf. Accessed 1 November 2010.
28. Mathias A, Koziara J, Wei L, Warren D, Kearney BP. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P-13]. In: 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, Florida, 13-15 April 2011.